(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 October 2009 (15.10.2009)

PCT

(10) International Publication Number
WO 2009/125226 A1

(51) **International Patent Classification**:
A61K 9/16 (2006.01) *A61K 31/165* (2006.01)

(21) **International Application Number**:
PCT/GB2009/050353

(22) **International Filing Date**:
9 April 2009 (09.04.2009)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/043,491 9 April 2008 (09.04.2008) US

(71) **Applicant** *(for all designated States except US)*: **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(71) **Applicant** *(for MG only)*: **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **BATEMAN, Nicola, Frances** [GB/GB]; AstraZeneca, Charter Way, Macclesfield, Cheshire SK10 2NA (GB). **MACFAUL, Philip, Alexander** [GB/GB]; AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **NASH, Ian, Alun** [GB/GB]; AstraZeneca Intellectual Property, AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(74) **Agent**: **ASTRAZENECA AB**; AstraZeneca Intellectual Property, S-151-85 Södertälje (SE).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— *with international search report (Art. 21(3))*

WO 2009/125226 A1

(54) **Title**: PHARMACEUTICAL DEPOT COMPRISING N-{5- T (CYCLOPROPYLAMINO) CARBONYL] -2-METHYLPHENYL}-3-FLU0R0-4- (PYRIDIN-2-YLMETHOX Y) BENZAMIDE

Figure 1



(57) **Abstract**: A pharmaceutical depot comprising (i) *N*-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide, or a pharmaceutically-acceptable salt thereof, as a pharmaceutical agent (PA) and (ii) a polymer which degrades to create an acidic microclimate, wherein the PA is released from the polymer upon polymer degradation.